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In the past 20 years, spending in all areas of health care has increased dra-
matically. In 1980, the national health expenditure per capita was $1,067. In
2000, our country spent $4,681 per person on health-care [6]. Expenditures on
prescription drugs have played a major role in driving up our country’s health
care costs, in fact, increasing at a rate twice as great as overall health care
costs [6]. My honors thesis examined the reasons for skyrocketing prescription
drug spending, methods to create less expensive prescription drug delivery sys-
tems, and economic and ethical issues within the pharmaceutical industry. The
following is a brief summary of the main points in my paper.
Spending on prescription drugs in the last 20 years has increased largely due
to drugs being more effective and replacing more costly procedures done in a
hospital or by a physician [1]. Many of the newer drugs on the market are known
as “lifestyle” drugs. People who are taking these medications are not facing
a life or death situation, but may be suffering from arthritis, concerned about
high cholesterol, or may be battling depression. Pharmaceutical companies
are spending large sums of money advertising such drugs in magazines, on
television, and at sporting events. Such advertising is known as direct-to-
consumer advertising, which can be beneficial for consumers because it makes
them more aware of cures for their health concerns, but arguably artificially
drives up the demand for the drug by people who might not really need the
medication [4].
The cost in terms of time and money to develop a new drug and meet all
regulations is enormous. The Tufts Center for the Study of Drug Development
found a pharmaceutical company typically spends about $800 million over a
period of ten to fifteen years to develop a new drug [5]. A new drug must
undergo rigorous clinical studies under the watchful eye of the Food & Drug
Administration, and volunteers must test the drug to assure that there will
be no harmful effects once it reaches the market place [5]. Naturally, a phar-
maceutical company will want to be rewarded if it creates a product that is
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benefiting consumers. Therefore, for each new drug that reaches the market,
the company benefits from having the exclusive right to sell the drug for 20
years. Although patents drive up the costs of prescription drugs, they must be
used as a financial incentive to motivate development of new drugs [2, p. 451].
Managed care organizations and pharmacy benefit managers have been de-
veloping methods of controlling prescription drug expenditures, but at the same
time making sure patient care is not being sacrificed. A primary method used
today is the prescription drug formulary. The Managed Care Handbook defines
a drug formulary by the following: a preferred list of medications developed
by the health plan or pharmacy benefit manager to guide physician prescribing
and pharmacy dispensing. The purpose of a drug formulary is to control inven-
tory and encourage the use of the most cost-effective products [3]. There are
several factors a drug must satisfy in order to be placed on a formulary. The
following criteria are considered: source of supply, reliability of manufacturer
and distributor, drug class, similarity to existing drugs, clinical advantages,
dosage ranges, and cost comparisons [3].
Pharmacy benefit managers and other health care plans are able to manage
a drug benefit for a large group of people, and therefore have the leverage to
negotiate with retail pharmacies and manufacturers for discounts [7]. Pharma-
ceutical companies are willing to give discounts and rebates to large pharmacy
benefit plans in return for an increase in market share for their drug. Pharmacy
benefit plans will often make the consumer pay more out-of-pocket for a drug
that is not on the formulary and costs more, thus giving the consumer incentive
to choose the drug on the formulary. These additional costs are usually added
through a higher copay (amount paid by the consumer) upon purchase of a
prescription at the pharmacy [7].
It is probable that formularies will continue to be incorporated in the pre-
scription drug benefit sections of health plans. Americans want the best drugs
possible for their ailments, but at a price that they can afford. With our added
dependence on prescription drugs for our health needs, a well developed and
managed formulary can help our society by serving two of our basic prescription
drug wishes: access and affordability.
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